ReviewReviews in endocrine & metabolic disorders2006
Molecular regulation of osteoclast activity.
Review in Reviews in endocrine & metabolic disorders, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02972138 (Vitamin D Supplementation and Anti-resorptive Therapy), which is not on this map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vitamin D Supplementation and Anti-resorptive Therapy (Bisphosphonates) Treatment of Young Adult Patients With Sickle Cell Disease
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- The therapeutic potential of terpenes in periodontal disease: a systematic review of pre-clinical animal studies.Inflammopharmacology · 2025Pooled it
- Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review.Current drug targets · 2018Pooled it
- Trial
- Comparative Bone-Protective Effects of Tocotrienol Isomers from Palm and Annatto in Dexamethasone-Induced Osteoporotic Male Rats.International journal of molecular sciences · 2025Article
- Coptidis Rhizoma Water Extract Attenuates RANKL-Induced Osteoclast Differentiation via MAPK, Akt, and NF-κB Pathways and Prevents Ovariectomy (OVX)-Mediated Bone Loss.International journal of molecular sciences · 2025Article
- Characterization of a periodontal-inflammatory microRNA profile during multibracket orthodontic treatment in adolescents.Scientific reports · 2025Article
- Emerging therapeutic strategies targeting bone signaling pathways in periodontitis.Journal of periodontal research · 2025Review
- Chordoma cells possess bone-dissolving activity at the bone invasion front.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Cedrol alleviates postmenopausal osteoporosis in rats through inhibiting the activation of the NF-κB signaling pathway.In vitro cellular & developmental biology. Animal · 2024Article
- Prostate cancer and bone: clinical presentation and molecular mechanisms.Endocrine-related cancer · 2023Review
- Open Thy Lattice Osteoclast, Resorb me!The Journal of cell biology · 2023Article
- Tocotrienol as a Protecting Agent against Glucocorticoid-Induced Osteoporosis: A Mini Review of Potential Mechanisms.Molecules (Basel, Switzerland) · 2022Review
- Systemic Dietary Hesperidin Modulation of Osteoclastogenesis, Bone Homeostasis and Periodontal Disease in Mice.International journal of molecular sciences · 2022Article
- Article
- Asiatic Acid Attenuates Osteoporotic Bone Loss in Ovariectomized Mice Through Inhibiting NF-kappaB/MAPK/ Protein Kinase B Signaling Pathway.Frontiers in pharmacology · 2022Article
- Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review.European journal of oral sciences · 2021Review
- Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease.Frontiers in cell and developmental biology · 2021Review
- Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling.Frontiers in pharmacology · 2021Article
- Quantification of Osteoclasts in Culture, Powered by Machine Learning.Frontiers in cell and developmental biology · 2021Article
- Switch of macrophage fusion competency by 3D matrices.Scientific reports · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Osteoclasts are multinucleated cells derived from hematopoietic precursors that are primarily responsible for the degradation of mineralized bone during bone development, homeostasis and repair. In various skeletal disorders such as osteoporosis, hypercalcemia of malignancy, tumor metastases and Paget's disease, bone resorption by osteoclasts exceeds bone formation by osteoblasts leading to decreased bone mass, skeletal fragility and bone fracture. The overall rate of osteoclastic bone resorption is regulated either at the level of differentiation of osteoclasts from their monocytic/macrophage precursor pool or through the regulation of key functional proteins whose specific activities in the mature osteoclast control its attachment, migration and resorption. Thus, reducing osteoclast numbers and/or decreasing the bone resorbing activity of osteoclasts are two common therapeutic approaches for the treatment of hyper-resorptive skeletal diseases. In this review, several of the key functional players involved in the regulation of osteoclast activity will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.